Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Of Japan Obtains Approval To Launch Hepatitis Drug Clevudine In Philippines

This article was originally published in PharmAsia News

Executive Summary

Japanese drug maker Eisai obtained March 13 approval to market the chronic hepatitis B drug clevudine in the Philippines from the Bureau of Food and Drugs. Eisai's Philippine subsidiary, Hi-Eisai Pharmaceutical, will launch the drug under the name Levovir. There are an estimated 8 million patients infected with the hepatitis B virus in the Philippines. Eisai has also applied for regulatory approval to market clevudine in India, Indonesia, Malaysia and Thailand and plans to file for approval to market the drug in Singapore and Vietnam. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel